en · de · es · fr · pt
sr9009-notes.peptides6608.com › Topic › Identity, Handling, And Regulation — Evidence Review

Identity, Handling, And Regulation — Evidence Review

By Editorial Desk · published 2026-03-28 · last reviewed 2026-04-18 · Topic

The short version of nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-04-18. Anything still debated is marked as such rather than presented as settled.

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Sr9009 at a glance

PropertyValueNotes
AppearanceWhite to off-white solidVisual inspection is not sufficient for identity.
SolubilitySoluble in DMSO and ethanolLow solubility in water.
Typical storage-20 °C, desiccated, darkProtect from repeated temperature changes.
Common analytical methodLC-MS or HPLC-UVReference standard required for comparison.
Common synonymsSR9009; Stenabolic; REV-ERB agonistVendor naming may vary.

Detection, Regulation, and Misconceptions

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Related pages on this site

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

Supporting material

=== Physiological roles in organs and tissues === FcRn is expressed on antigen-presenting leukocytes such as dendritic cells and is also expressed in neutrophils to help clear opsonized bacteria. In the kidneys, FcRn is expressed on epithelial cells called podocytes to prevent IgG and albumin from clogging the glomerular filtration barrier. Current studies are investigating FcRn in the liver because there are relatively low concentrations of both IgG and albumin in liver bile despite high concentrations in the blood. Studies have also shown that FcRn-mediated transcytosis is involved with the trafficking of the HIV-1 virus across genital tract epithelium.

== Types == All human rabies vaccines are inactivated vaccines made by inactivation of virus-containing material. The oldest kind are nerve tissue vaccines, made from the nerve tissue of rabies-infected animals. They are still approved in a few countries. They are not recommended by the WHO as they are less effective and have greater side effects. They also contain impurities of nervous origin such as myelin. Instead, WHO recommends Cell Culture Vaccines and Embryonated egg-based vaccines (CCEEV), where the virus is grown in cultured cells or fertilized duck eggs before being inactivated. The virus is then separated out and used for making the vaccine by ultrafiltration or ultracentrifugation. The process renders CCEEVs purer and more concentrated, which contributes to its safety and effectiveness. As with the older type, CCEEVs can be used in both pre- and post-exposure vaccinations. Specific CCEEVs are classified by the type of cell the virus is grown in and include:

According to Ren Naiqiang, a contemporary who had worked under Liu's government, it was only through the promotion of Buddhism that Liu was able to stabilize his rule after the retreat to Xikang. Upon arriving in Kangding, Liu reportedly invited several famous lamas to gather at his residence to teach him scriptures and dharma. Liu would turn prayer wheels and chant mantras. After these sessions, the lamas spread the word that Liu was in fact the reincarnation of the protector Vajrapani, which greatly enhanced his reputation amongst the people of Kham.

=== Information technology === The last decade has seen a proliferation of information technology use in the planning and conduct of clinical trials. Clinical trial management systems are often used by research sponsors or CROs to help plan and manage the operational aspects of a clinical trial, particularly with respect to investigational sites. Advanced analytics for identifying researchers and research sites with expertise in a given area utilize public and private information about ongoing research. Web-based electronic data capture (EDC) and clinical data management systems are used in a majority of clinical trials to collect case report data from sites, manage its quality and prepare it for analysis. Interactive voice response systems are used by sites to register the enrollment of patients using a phone and to allocate patients to a particular treatment arm (although phones are being increasingly replaced with web-based (IWRS) tools which are sometimes part of the EDC system). While patient-reported outcome were often paper based in the past, measurements are increasingly being collected using web portals or hand-held ePRO (or eDiary) devices, sometimes wireless. Statistical software is used to analyze the collected data and prepare them for regulatory submission. Access to many of these applications are increasingly aggregated in web-based clinical trial portals.

Sources: en.wikipedia.org

Supporting material

Over the November 2016 Thanksgiving holiday weekend, President-Elect Donald Trump tweeted that he was in talks with Carrier Management to keep the factory in Indiana and not move to Mexico. On November 30, 2016, Carrier announced that it had negotiated an agreement with President-elect Trump and Vice President-elect Mike Pence to continue manufacturing gas furnaces in Indianapolis, in addition to retaining engineering and headquarters staff, preserving more than 1,000 jobs in Indianapolis. The agreement included a state incentive package of about $7 million over 10 years. The number of jobs saved was later revised down to 800. In May 2017, as part of their previously announced plan, Carrier told the state of Indiana that it will cut 632 jobs from its Indianapolis factory. Layoffs began at the end of July 2017, with each worker receiving one week's salary for each year of employment, education and job training, plus 6 months of health insurance as part of the severance package. The New York Times reported on August 10, 2018, that Carrier's Indianapolis furnace plant was plagued by low morale and absenteeism because "employees share a looming sense that a factory shutdown is inevitable — that Carrier has merely postponed the closing until a more politically opportune moment." On November 26, 2018, United Technologies announced that it would spin off UTC Climate, Controls & Security as an independent company known as Carrier Global Corporation. In April 2020, United Technologies announced that the separation and spin-off of Carrier had been completed.

=== Shellworlds === Shellworlds are introduced in Matter, and consist of multilayered levels of concentric spheres in four dimensions held up by countless titanic interior towers. Their extra dimensional characteristics render some products of Culture technology too dangerous to use and yet others ineffective, notably access to hyperspace. About 4000 were built millions of years ago as vast machines intended to cast a forcefield around the whole of the galaxy for unknown purposes; less than half of those remain at the time of Matter, many having been destroyed by a departed species known as the Iln. The species that developed this technology, known as the Veil or the Involucra, are now lost, and many of the remaining shellworlds have become inhabited, often by many different species throughout their varying levels. Many still hold deadly secret defence mechanisms, often leading to great danger for their new inhabitants, giving them one of their other nicknames: Slaughter Worlds.

Madecassic acid is a pentacyclic triterpenoid compound that occurs naturally in several plant species. Madecassic acid is a member of the ursane-type triterpenoids and is structurally similar to Asiatic acid, differing by the presence of a hydroxyl group at the C-2 position.

Sources: en.wikipedia.org

Notes from published material

=== Other functions === Knockout and molecular studies in mice suggest that this kinase is important for regulating behavioural response to morphine and alcohol. It also plays a role lipopolysaccharide (LPS)-mediated signaling in activated macrophages and in controlling anxiety-like behavior.

Specifically, using subjective well-being data from China, the authors find that homeownership is associated with higher levels of life satisfaction, although this happiness premium is larger for people who have full ownership compared to those who have only a minor ownership stake in their home." According to the latest systematic review of the economic literature on life satisfaction, living in rural areas seems to have some association with well-being, because the included studies tend to control for income and rural areas tend to be poor. Income has a high effect on happiness and incomes are higher in urban areas, so chasing a rural lifestyle at the expense of income may be a 'grass is always greener' move. Adults who live with parents also tend to have poorer levels of well-being.

=== Evolution and biogeography === One fossil seed of †Viola rimosa has been extracted from borehole samples of the Middle Miocene fresh water deposits in Nowy Sącz Basin, West Carpathians, Poland. The genus is thought to have arisen in South America, most likely the Andes.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 usually analyzed?

Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.

What storage conditions are typical?

The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.

Is SR9009 legal to purchase?

Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Network